Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout Flares

ClinicalTrials.gov ID: NCT00610363

Public ClinicalTrials.gov record NCT00610363. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study, Tolerability, and Efficacy of Rilonacept for the Prevention of Gout Flares During Initiation of Allopurinol Therapy

Study identification

NCT ID
NCT00610363
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Regeneron Pharmaceuticals
Industry
Enrollment
83 participants

Conditions and interventions

Conditions

Interventions

  • Rilonacept Biological
  • Placebo (for Rilonacept) Other

Biological · Other

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2007
Primary completion
Sep 30, 2008
Completion
Sep 30, 2008
Last update posted
May 1, 2017

2007 – 2008

United States locations

U.S. sites
34
U.S. states
20
U.S. cities
33
Facility City State ZIP Site status
Not listed San Diego California 92108
Not listed Santa Maria California 93454
Not listed Whittier California 90601
Not listed Colorado Srings Colorado 80910
Not listed DeLand Florida 32720
Not listed Ocala Florida 34471
Not listed Orlando Florida 32804
Not listed St. Petersburg Florida 33710
Not listed Tampa Florida 33614
Not listed Tampa Florida
Not listed Dunwoody Georgia 30338
Not listed Honolulu Hawaii 96814
Not listed Boise Idaho 83702
Not listed Indianapolis Indiana 46268
Not listed South Bend Indiana 46601
Not listed Owensboro Kentucky 42303
Not listed Wheaton Maryland 20902
Not listed Billings Montana 59101
Not listed Omaha Nebraska 68114
Not listed Reno Nevada 89502
Not listed Albany New York 12206
Not listed Plainview New York 11803
Not listed Roslyn New York 11576
Not listed Monroe North Carolina 28112
Not listed Raleigh North Carolina 27612
Not listed Cincinnati Ohio 45242
Not listed Mayfield Village Ohio 44143
Not listed Oklahoma City Oklahoma 73112
Not listed Duncansville Pennsylvania 16635
Not listed West Reading Pennsylvania 19611
Not listed Charleston South Carolina 29406
Not listed Grenville South Carolina 29601
Not listed Dallas Texas 75235
Not listed Spokane Washington 99204

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00610363, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 1, 2017 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00610363 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →